 |
 |
Anyone heard of Zelapar? New Therapy For Parkinson's Disease Patients (NAPSA)-In the United States, an estimated 1.5 million Americans are afflicted with Parkinson's disease (PD), with more than 60,000 new cases diagnosed each year. While the condition usually develops after the age of 65, 40 percent of people diagnosed are under age 60. Parkinson's disease is a chronic, progressive disorder of the central nervous system that belongs to a group of conditions called motor system disorders. It affects nearly equal numbers of men and women, with no obvious social, ethnic, economic or geographic boundaries. There presently is no cure for the disease, and the cause is unknown. Levodopa/carbidopa is commonly used early in the treatment of Parkinson's disease, but as the disease progresses it becomes increasingly difficult to adequately control symptoms with this medication. In fact, Parkinson's disease patients may experience many hours during the day in which their symptoms return as a result of medication wearing off. This wearing off is known as "off" time. The good news is that the U.S. Food and Drug Administration (FDA) approved Zelapar(r) (selegiline HCl) Orally Disintegrating Tablets, a once-daily adjunct therapy for Parkinson's disease patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. Utilizing a unique orally dissolving drug delivery system, Zelapar has been shown to reduce "off" time, on average, by more than two hours per day. Marketed by Valeant Pharmaceuticals International, Zelapar is a selective and irreversible monoamine oxidase type-B (MAO-B) inhibitor and is the first Parkinson's disease treatment to use a novel delivery system called Zydis(r) Technology, which allows the oral tablets to dissolve within seconds in the mouth and deliver more active drug at a lower dose. For full prescribing and safety information on Zelapar, please visit www.zelapar.com, or for product-related questions, call Valeant Pharmaceuticals International at 1-877-361-2719. System and Method for Display Ads have a Patent Pending. Click Here for More Information ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn